本帖最后由 老马 于 2012-1-13 21:20 编辑
% U* C+ }4 F) N/ ?/ f8 z+ {/ I9 P! L& F
爱必妥和阿瓦斯丁的比较1 F/ B2 O2 _) Z2 i
% G$ A8 E7 y/ l, l% S
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
# h. d: d$ t! {# {( V
/ W% X7 D5 C" N" h5 p
. ~4 A& F: y6 a3 jhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
" l# x) Z7 x7 `==================================================
- n x# l- w; j/ w% Z! ^Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)/ d. ~1 k* I2 E: e3 b
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.4 ? k9 a: {' M* C
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.2 Y9 k0 g* F( D3 k
|